TB-500 (Thymosin Beta-4): What the Research Shows About This Healing Peptide

What it is

TB-500 is a lab-made peptide that copies the active region of thymosin beta-4, a protein found in nearly every human cell. Thymosin beta-4, usually written Tβ4, is 43 amino acids long. It is concentrated in wound fluid, blood platelets, and tissues that are busy repairing themselves.

Tβ4 was first isolated from the thymus gland and studied for its part in training immune T-cells. Later work showed that its main job is actin regulation. Actin is the protein that forms a cell’s internal scaffolding, which the cell uses to hold its shape, move, and divide.

One distinction matters throughout this page. Almost all published research is on Tβ4 itself, the natural protein. TB-500 is the synthetic version sold by research chemical suppliers, related but not identical, so claims about “TB-500” mostly rest on studies of its parent molecule.

What it is studied for

Tβ4 has been studied for wound healing, inflammation, new blood vessel growth, heart repair after a heart attack, recovery from brain injury, corneal healing, and hair growth. Nearly all of that work is in animals or in cells.

Two Tβ4-based drugs reached human trials: eye drops for dry eye disease and an intravenous drug for heart attack patients. Neither involved the injected, whole-body use that draws most of the interest in TB-500.

What the evidence actually shows

In humans

The furthest any Tβ4 product has gone is RGN-259, a Tβ4 eye drop. It completed Phase III trials for dry eye disease with reported positive results, which makes it the closest a Tβ4-derived treatment has come to market (Dunn et al., 2010).

A second product, RGN-352, was developed by RegeneRx Biopharmaceuticals for heart repair after a heart attack. A Phase I safety trial found it well tolerated, but results from the Phase I/II program were mixed and the wider clinical program did not proceed as hoped (Smart et al., 2007), (Crockford et al., 2010).

For injected TB-500 as a general healing agent, there is no human efficacy data at all. That is the central fact of this page.

In animals

Wound healing is the best-studied area. In rats with full-thickness skin wounds, 5 μg of Tβ4 applied to the wound increased contraction, re-epithelialization, and collagen deposition compared with untreated wounds. Treated wounds also had a better-organized extracellular matrix and less scarring, meaning the repaired tissue looked more like the original (Malinda et al., 1999).

The same research found that Tβ4 promotes angiogenesis, the growth of new blood vessels, which healing tissue needs for oxygen and nutrients. In lab dishes it prompts endothelial cells to migrate and form tube-like structures. The proposed mechanism involves raising VEGF, a growth signal for blood vessels (Malinda et al., 1999).

Tβ4 also calms inflammation in animal injury models. It lowered pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, the signals behind the pain, swelling, and redness of a fresh injury. In rats with corneal injury it reduced the influx of inflammatory cells and suppressed NF-κB, a master switch for inflammatory genes (Sosne et al., 2007).

Heart repair is the other well-studied area. In mice given a heart attack, or myocardial infarction, Tβ4 reduced the size of the damaged area and improved heart function. It helped heart muscle cells survive and activated the heart’s own progenitor cells, an early form of repair cell (Smart et al., 2007). Studies in mice and pigs showed better cardiac function and less scarring (Crockford et al., 2010).

In rats with traumatic brain injury, Tβ4 at 6 mg/kg injected into the abdominal cavity improved neurological function and reduced brain swelling. It also promoted neurogenesis on the injured side, and treated rats did better on movement and memory tests (Xiong et al., 2011).

Tβ4 promoted hair growth in mice, apparently by helping hair follicle stem cells migrate and mature. There are no human data on this (Philp et al., 2004).

As for how it works, Tβ4 binds G-actin, the loose single units of actin, and stops them from assembling into filaments too early. Keeping that pool available lets cells rebuild their scaffolding quickly, which they need in order to migrate to a wound, divide, form vessels, and pass signals (Goldstein et al., 2005). This comes from cell and animal studies, not from confirmed human pharmacology.

TB-500 is also used in veterinary medicine, mainly for tendon injuries in horses, which resemble the connective tissue injuries behind much of the human interest. We could not find a controlled equine study to cite, so we treat the reported benefits in horses as unverified.

From user reports

People who inject TB-500 mostly describe it as well tolerated. They report a brief head rush or lightheadedness after injecting, temporary tiredness early in a course, injection-site reactions, and occasional mild headache. These are personal accounts, not measurements.

How it is used in studies

Routes vary by study. Wound studies applied Tβ4 directly to the wound (5 μg in rats), eye studies used drops, the brain injury study injected 6 mg/kg into the abdominal cavity, and the cardiac drug was given intravenously. No human study has established a dose for subcutaneous injection.

What follows is community practice, not a studied protocol. People describe a loading phase of 2 to 2.5 mg twice a week for 4 to 6 weeks, about 4 to 5 mg a week. After that they report 2 to 2.5 mg once a week or every two weeks for another 4 to 8 weeks.

They inject under the skin at any convenient site, on the reasoning that Tβ4 circulates through the whole body rather than acting where it lands. Those are milligram doses, roughly ten times the microgram doses reported for BPC-157. The gap reflects different pharmacodynamics and distribution, not a direct comparison of strength.

TB-500 is typically sold as a 5 mg freeze-dried powder. Users mix it with 1 to 2 mL of bacteriostatic water, keep it refrigerated at 2 to 8°C, and use it within 3 to 4 weeks. See the storage and reconstitution guide for general handling. None of this is a dosing recommendation.

Side effects and unknowns

Human safety data for TB-500 as a healing agent are limited to the user reports above and the wider Tβ4 literature. The RGN-352 Phase I trial found intravenous Tβ4 well tolerated, but that was a different product, route, and setting.

The main theoretical concern is cancer. The same properties that help healthy cells migrate and grow new blood vessels could, in theory, help a tumor do the same. Elevated Tβ4 has been found in some tumor types, and the studies conflict: some show no tumor promotion, while others link Tβ4 to more aggressive tumors in correlational data (Ryu et al., 2012). Whether injecting Tβ4 changes tumor behavior in people is not established.

Tβ4 may also widen blood vessels, which could briefly affect blood pressure.

The biggest gap is time. No long-term human safety study of TB-500 exists, so we don’t know what months or years of use do. Anyone dealing with an injury or medical condition should talk to a healthcare provider rather than rely on this page.

Legal status

In the United States, TB-500 is not FDA approved for human use and is sold as a research chemical. The FDA has tightened its position on compounded thymosin beta-4 products and has sent warning letters to some pharmacies.

Australia classes it as Schedule 4, prescription-only. It is used there in veterinary medicine, particularly for horses, under veterinary supervision.

WADA explicitly prohibits thymosin beta-4 under Section S2, which covers peptide hormones, growth factors, and related substances, both in and out of competition. Several athletes and horse trainers have been sanctioned for it. It is banned in horse racing in most jurisdictions, and its early notoriety came from racing cases.

Bottom line

Thymosin beta-4 has a broad and fairly consistent animal record for healing, and two drugs derived from it have been tested in people, one for dry eye and one for the heart. Injected TB-500 for general recovery, the use most people care about, has no human efficacy data and no long-term safety data. If you need proof that it works in humans, that proof does not exist yet.

Frequently Asked Questions

What is the difference between TB-500 and thymosin beta-4?

Thymosin beta-4 is the natural protein, and most published research used it. TB-500 is a synthetic copy of its active region, sold by research chemical suppliers. They are similar in function but not identical molecules.

Does TB-500 need to be injected near the injury?

Community protocols say no. People inject it under the skin anywhere, because Tβ4 travels through the bloodstream rather than acting locally. That differs from BPC-157, which users often describe as working better near the site of concern.

Is TB-500 detectable in drug tests?

Standard workplace panels do not test for it. Specialized anti-doping tests can detect thymosin beta-4, and WADA bans it, so athletes in tested sports should assume it will be found.

How does TB-500 compare to BPC-157?

They are usually discussed as complementary rather than interchangeable. BPC-157 is studied for local healing through blood vessel growth and growth-factor signaling, while TB-500 is studied as a whole-body peptide working through actin regulation and broad anti-inflammatory effects. GHK-Cu is a third option, studied for collagen remodeling. Our injury recovery guide compares them in detail.

Is TB-500 related to thymosin alpha-1?

Only by name and origin. Thymosin alpha-1 also comes from the thymus, but it is studied for immune regulation rather than healing. Growth hormone secretagogues such as ipamorelin and CJC-1295 come up in recovery discussions for a different reason, raising growth hormone; see the muscle growth guide.

Is there any human clinical data for TB-500?

Not for injected TB-500 as a healing agent. The nearest human data come from RGN-259 eye drops, which completed Phase III for dry eye, and the RGN-352 cardiac program, which reached Phase I safety testing. Neither tested subcutaneous injection for general healing.

What are the main safety concerns?

The absence of human safety data for the way TB-500 is actually used. The theoretical cancer question matters if an undiagnosed tumor is present, and long-term effects are unknown. User reports of good tolerance are not a substitute for controlled studies.

References

1. Goldstein AL, et al. “Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.” Trends Mol Med. 2005;11(9):421-9. PubMed
2. Sosne G, et al. “Thymosin beta 4 suppression of corneal NFkappaB: A potential anti-inflammatory pathway.” Exp Eye Res. 2007;84(4):663-9. PubMed
3. Malinda KM, et al. “Thymosin beta4 accelerates wound healing.” J Invest Dermatol. 1999;113(3):364-8. PubMed
4. Smart N, et al. “Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization.” Nature. 2007;445(7124):177-82. PubMed
5. Philp D, et al. “Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development.” Mech Ageing Dev. 2004;125(2):113-5. PubMed
6. Dunn SP, et al. “Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4.” Ann N Y Acad Sci. 2010;1194:199-206. PubMed
7. Xiong Y, et al. “Thymosin beta4 treatment of traumatic brain injury in the rat.” J Neurosurg. 2012;116(5):1081-92. PubMed
8. Crockford D, et al. “Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications.” Ann N Y Acad Sci. 2010;1194:179-89. PubMed
9. Ryu YK, et al. “Thymosin beta-4 expression in hepatocellular carcinoma.” Pathology. 2012;44(4):335-8. PubMed

See also

• Peptide
  BPC-157: What the Research Actually Shows About This Healing Peptide

  A plain review of the animal research on BPC-157, what it suggests about healing, and why none of it has been confirmed in people.

• Peptide
  GHK-Cu (Copper Peptide): Research, Mechanism, and Evidence for Tissue Repair

  GHK-Cu is a copper-carrying peptide your body makes naturally, studied mainly as a skin cream for aging skin and, in animals, for wound healing.

• Peptide
  LL-37: What the Research Shows About This Human Antimicrobial Peptide

  LL-37 is the only cathelicidin peptide humans make, a 37-amino-acid molecule that kills bacteria directly and helps close wounds. It is well studied in the lab and in animals, and injecting it has never been tested in a person.